Drug Profile
Research programme: telomere oligonucleotides - Micromet/SemaCo
Latest Information Update: 18 Mar 2008
Price :
$50
*
At a glance
- Originator SemaCo
- Developer Micromet Inc
- Class Oligonucleotides
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer